[en] The rewiring of lipid metabolism is a major adaptation observed in cancer, and it is
generally associated with the increased aggressiveness of cancer cells. Targeting lipid metabolism is
therefore an appealing therapeutic strategy, but it requires a better understanding of the specific roles
played by the main enzymes involved in lipid biosynthesis. Lipin-1 is a central regulator of lipid
homeostasis, acting either as an enzyme or as a co-regulator of transcription. In spite of its important
functions it is only recently that several groups have highlighted its role in cancer. Here, we will
review the most recent research describing the role of lipin-1 in tumor progression when expressed
by cancer cells or cells of the tumor microenvironment. The interest of its inhibition as an adjuvant
therapy to amplify the effects of anti-cancer therapies will be also illustrated.
Ferreira, L.M.; Hebrant, A.; Dumont, J.E. Metabolic reprogramming of the tumor. Oncogene 2012, 31, 3999–4011. [CrossRef] [PubMed]
Ackerman, D.; Simon, M.C. Hypoxia, lipids, and cancer: Surviving the harsh tumor microenvironment. Trends Cell Biol. 2014, 24, 472–478. [CrossRef]
Warburg, O.; Wind, F.; Negelein, E. The Metabolism of Tumors in the Body. J. Gen. Physiol. 1927, 8, 519–530. [CrossRef] [PubMed]
Payen, V.L.; Porporato, P.E.; Baselet, B.; Sonveaux, P. Metabolic changes associated with tumor metastasis, part 1: Tumor pH, glycolysis and the pentose phosphate pathway. Cell. Mol. Life Sci. 2016, 73, 1333–1348. [CrossRef]
Porporato, P.E.; Payen, V.L.; Baselet, B.; Sonveaux, P. Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. Cell. Mol. Life Sci. 2016, 73, 1349–1363. [CrossRef] [PubMed]
Snaebjornsson, M.T.; Janaki-Raman, S.; Schulze, A. Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metab. 2020, 31, 62–76. [CrossRef]
Bensaad, K.; Favaro, E.; Lewis, C.A.; Peck, B.; Lord, S.; Collins, J.M.; Pinnick, K.E.; Wigfield, S.; Buffa, F.M.; Li, J.L.; et al. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014, 9, 349–365. [CrossRef]
Rohrig, F.; Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 2016, 16, 732–749. [CrossRef]
Beckers, A.; Organe, S.; Timmermans, L.; Scheys, K.; Peeters, A.; Brusselmans, K.; Verhoeven, G.; Swinnen, J.V. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007, 67, 8180–8187. [CrossRef]
De Schrijver, E.; Brusselmans, K.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003, 63, 3799–3804.
Zaidi, N.; Royaux, I.; Swinnen, J.V.; Smans, K. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell-and environment-dependent mechanisms. Mol. Cancer Ther. 2012, 11, 1925–1935. [CrossRef] [PubMed]
Bacci, M.; Lorito, N.; Smiriglia, A.; Morandi, A. Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. Trends Cancer 2021, 7, 198–213. [CrossRef] [PubMed]
Donkor, J.; Sariahmetoglu, M.; Dewald, J.; Brindley, D.N.; Reue, K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 2007, 282, 3450–3457. [CrossRef]
Harris, T.E.; Finck, B.N. Dual function lipin proteins and glycerolipid metabolism. Trends Endocrinol. Metab. 2011, 22, 226–233. [CrossRef] [PubMed]
Kennedy, E.P. The biological synthesis of phospholipids. Can. J. Biochem. Physiol. 1956, 34, 334–348. [CrossRef]
Csaki, L.S.; Dwyer, J.R.; Fong, L.G.; Tontonoz, P.; Young, S.G.; Reue, K. Lipins, lipinopathies, and the modulation of cellular lipid storage and signaling. Prog. Lipid Res. 2013, 52, 305–316. [CrossRef]
Chae, M.; Jung, J.Y.; Bae, I.H.; Kim, H.J.; Lee, T.R.; Shin, D.W. Lipin-1 expression is critical for keratinocyte differentiation. J. Lipid Res. 2016, 57, 563–573. [CrossRef]
Koh, Y.K.; Lee, M.Y.; Kim, J.W.; Kim, M.; Moon, J.S.; Lee, Y.J.; Ahn, Y.H.; Kim, K.S. Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma 2. J. Biol. Chem. 2008, 283, 34896–34906. [CrossRef]
Zhang, P.; Verity, M.A.; Reue, K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab. 2014, 20, 267–279. [CrossRef]
Romani, P.; Brian, I.; Santinon, G.; Pocaterra, A.; Audano, M.; Pedretti, S.; Mathieu, S.; Forcato, M.; Bicciato, S.; Manneville, J.B.; et al. Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP. Nat. Cell Biol. 2019, 21, 338–347. [CrossRef]
Finck, B.N.; Gropler, M.C.; Chen, Z.; Leone, T.C.; Croce, M.A.; Harris, T.E.; Lawrence, J.C., Jr.; Kelly, D.P. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006, 4, 199–210. [CrossRef]
Donkor, J.; Zhang, P.; Wong, S.; O’Loughlin, L.; Dewald, J.; Kok, B.P.; Brindley, D.N.; Reue, K. A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2. J. Biol. Chem. 2009, 284, 29968–29978. [CrossRef] [PubMed]
Kim, H.B.; Kumar, A.; Wang, L.; Liu, G.H.; Keller, S.R.; Lawrence, J.C., Jr.; Finck, B.N.; Harris, T.E. Lipin 1 represses NFATc4 transcriptional activity in adipocytes to inhibit secretion of inflammatory factors. Mol. Cell Biol. 2010, 30, 3126–3139. [CrossRef]
Peterson, T.R.; Sengupta, S.S.; Harris, T.E.; Carmack, A.E.; Kang, S.A.; Balderas, E.; Guertin, D.A.; Madden, K.L.; Carpenter, A.E.; Finck, B.N.; et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146, 408–420. [CrossRef] [PubMed]
Phan, J.; Peterfy, M.; Reue, K. Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J. Biol. Chem. 2004, 279, 29558–29564. [CrossRef] [PubMed]
Jung, Y.; Kwon, S.; Ham, S.; Lee, D.; Park, H.H.; Yamaoka, Y.; Jeong, D.E.; Artan, M.; Altintas, O.; Park, S.; et al. Caenorhabditis elegans Lipin 1 moderates the lifespan-shortening effects of dietary glucose by maintaining omega-6 polyunsaturated fatty acids. Aging Cell 2020, 19, e13150. [CrossRef] [PubMed]
Lehmann, M. Diverse roles of phosphatidate phosphatases in insect development and metabolism. Insect Biochem. Mol. Biol. 2020, 103469. [CrossRef]
Schmitt, S.; Ugrankar, R.; Greene, S.E.; Prajapati, M.; Lehmann, M. Drosophila Lipin interacts with insulin and TOR signaling pathways in the control of growth and lipid metabolism. J. Cell Sci. 2015, 128, 4395–4406. [CrossRef]
Lutkewitte, A.J.; Finck, B.N. Regulation of Signaling and Metabolism by Lipin-mediated Phosphatidic Acid Phosphohydrolase Activity. Biomolecules 2020, 10, 1386. [CrossRef] [PubMed]
Reue, K.; Wang, H. Mammalian lipin phosphatidic acid phosphatases in lipid synthesis and beyond: Metabolic and inflammatory disorders. J. Lipid Res. 2019, 60, 728–733. [CrossRef] [PubMed]
Brohee, L.; Demine, S.; Willems, J.; Arnould, T.; Colige, A.C.; Deroanne, C.F. Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget 2015, 6, 11264–11280. [CrossRef]
Fan, X.; Weng, Y.; Bai, Y.; Wang, Z.; Wang, S.; Zhu, J.; Zhang, F. Lipin-1 determines lung cancer cell survival and chemotherapy sensitivity by regulation of endoplasmic reticulum homeostasis and autophagy. Cancer Med. 2018, 7, 2541–2554. [CrossRef]
He, J.; Zhang, F.; Tay, L.W.R.; Boroda, S.; Nian, W.; Levental, K.R.; Levental, I.; Harris, T.E.; Chang, J.T.; Du, G. Lipin-1 regulation of phospholipid synthesis maintains endoplasmic reticulum homeostasis and is critical for triple-negative breast cancer cell survival. FASEB J. 2017, 31, 2893–2904. [CrossRef]
Ingram, L.M.; Finnerty, M.C.; Mansoura, M.; Chou, C.W.; Cummings, B.S. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells. Lipids Health Dis. 2021, 20, 15. [CrossRef]
Santuario-Facio, S.K.; Cardona-Huerta, S.; Perez-Paramo, Y.X.; Trevino, V.; Hernandez-Cabrera, F.; Rojas-Martinez, A.; UscangaPerales, G.; Martinez-Rodriguez, J.L.; Martinez-Jacobo, L.; Padilla-Rivas, G.; et al. A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy. Mol. Med. 2017, 23, 101–111. [CrossRef]
Dinarvand, N.; Khanahmad, H.; Hakimian, S.M.; Sheikhi, A.; Rashidi, B.; Bakhtiari, H.; Pourfarzam, M. Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene. J. Cell. Physiol. 2020, 235, 5835–5846. [CrossRef]
Kim, J.Y.; Kim, G.; Lim, S.C.; Choi, H.S. LPIN1 promotes epithelial cell transformation and mammary tumourigenesis via enhancing insulin receptor substrate 1 stability. Carcinogenesis 2016, 37, 1199–1209. [CrossRef]
Zhao, S.; Li, J.; Zhang, G.; Wang, Q.; Wu, C.; Zhang, Q.; Wang, H.; Sun, P.; Xiang, R.; Yang, S. Exosomal miR-451a Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting LPIN1. Cell Physiol. Biochem. 2019, 53, 19–35. [CrossRef] [PubMed]
Yang, L.; Ma, H.L. MiRNA-584 suppresses the progression of ovarian cancer by negatively regulating LPIN1. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 1062–1071. [CrossRef] [PubMed]
Song, L.; Liu, Z.; Hu, H.H.; Yang, Y.; Li, T.Y.; Lin, Z.Z.; Ye, J.; Chen, J.; Huang, X.; Liu, D.T.; et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat. Commun. 2020, 11, 5842. [CrossRef] [PubMed]
Hou, J.; Karin, M.; Sun, B. Targeting cancer-promoting inflammation-have anti-inflammatory therapies come of age? Nat. Rev. Clin. Oncol. 2021. [CrossRef]
Wang, K.; Karin, M. Tumor-Elicited Inflammation and Colorectal Cancer. Adv. Cancer Res. 2015, 128, 173–196. [CrossRef]
Kwitkowski, V.E.; Prowell, T.M.; Ibrahim, A.; Farrell, A.T.; Justice, R.; Mitchell, S.S.; Sridhara, R.; Pazdur, R. FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010, 15, 428–435. [CrossRef] [PubMed]
Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449–456. [CrossRef]
Fang, Z.; Zhang, T.; Dizeyi, N.; Chen, S.; Wang, H.; Swanson, K.D.; Cai, C.; Balk, S.P.; Yuan, X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J. Biol. Chem. 2012, 287, 2090–2098. [CrossRef] [PubMed]
Saijo, K.; Imai, H.; Chikamatsu, S.; Narita, K.; Katoh, T.; Ishioka, C. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor. Cancer Sci. 2017, 108, 1469–1475. [CrossRef]
Imai, H.; Saijo, K.; Chikamatsu, S.; Kawamura, Y.; Ishioka, C. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11. Cancer Sci. 2021, 112, 792–802. [CrossRef] [PubMed]
Thorburn, A.; Thamm, D.H.; Gustafson, D.L. Autophagy and cancer therapy. Mol. Pharmacol. 2014, 85, 830–838. [CrossRef]
Zhang, J. Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo. Reprod. Sci. 2021, 28, 524–531. [CrossRef]
Byington, R.P. Beta-blocker heart attack trial: Design, methods, and baseline results. Beta-blocker heart attack trial research group. Control Clin. Trials 1984, 5, 382–437. [CrossRef]
Jamal, Z.; Martin, A.; Gomez-Munoz, A.; Brindley, D.N. Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol. J. Biol. Chem. 1991, 266, 2988–2996. [CrossRef]
Koul, O.; Hauser, G. Modulation of rat brain cytosolic phosphatidate phosphohydrolase: Effect of cationic amphiphilic drugs and divalent cations. Arch. Biochem. Biophys. 1987, 253, 453–461. [CrossRef]
Pantziarka, P.; Bouche, G.; Sukhatme, V.; Meheus, L.; Rooman, I.; Sukhatme, V.P. Repurposing Drugs in Oncology (ReDO) Propranolol as an anti-cancer agent. Ecancermedicalscience 2016, 10, 680. [CrossRef]
Pantziarka, P.; Bryan, B.A.; Crispino, S.; Dickerson, E.B. Propranolol and breast cancer-a work in progress. Ecancermedicalscience 2018, 12, ed82. [CrossRef]
Pasquier, E.; Andre, N.; Street, J.; Chougule, A.; Rekhi, B.; Ghosh, J.; Philip, D.S.J.; Meurer, M.; MacKenzie, K.L.; Kavallaris, M.; et al. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. EBioMedicine 2016, 6, 87–95. [CrossRef]
Rico, M.; Baglioni, M.; Bondarenko, M.; Laluce, N.C.; Rozados, V.; Andre, N.; Carre, M.; Scharovsky, O.G.; Menacho Marquez, M. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget 2017, 8, 2874–2889. [CrossRef]
Saha, J.; Kim, J.H.; Amaya, C.N.; Witcher, C.; Khammanivong, A.; Korpela, D.M.; Brown, D.R.; Taylor, J.; Bryan, B.A.; Dickerson, E.B. Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux. Front. Oncol. 2020, 10, 614288. [CrossRef]
Farah, B.L.; Sinha, R.A.; Wu, Y.; Singh, B.K.; Zhou, J.; Bay, B.H.; Yen, P.M. beta-Adrenergic agonist and antagonist regulation of autophagy in HepG2 cells, primary mouse hepatocytes, and mouse liver. PLoS ONE 2014, 9, e98155. [CrossRef]
Schonthal, A.H. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem. Pharmacol. 2013, 85, 653–666. [CrossRef] [PubMed]
Brohee, L.; Peulen, O.; Nusgens, B.; Castronovo, V.; Thiry, M.; Colige, A.C.; Deroanne, C.F. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. Sci. Rep. 2018, 8, 7050. [CrossRef]
Lucido, C.T.; Miskimins, W.K.; Vermeer, P.D. Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC. Cancers 2018, 10, 476. [CrossRef]
Farrow, J.M.; Yang, J.C.; Evans, C.P. Autophagy as a modulator and target in prostate cancer. Nat. Rev. Urol. 2014, 11, 508–516. [CrossRef] [PubMed]
Peterfy, M.; Phan, J.; Reue, K. Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis. J. Biol. Chem. 2005, 280, 32883–32889. [CrossRef]
Han, G.S.; Carman, G.M. Characterization of the human LPIN1-encoded phosphatidate phosphatase isoforms. J. Biol. Chem. 2010, 285, 14628–14638. [CrossRef] [PubMed]
